Research Programs Supported by Ovations for the Cure
Ovations for the Cure of Ovarian Cancer supports various research, awareness and patient programs each year. To date, we have directed over $1.5 million to ovarian cancer research initiatives and treatment programs. Here's where it has gone:
- $660,607 to the Dr. Ursula Matulonis-Madeline Franchi Fund at Dana-Farber Cancer Institute
- $350,000 to Brigham and Women's Hospital to fund the Desensitization Program
- $150,000 to Dana-Farber Cancer Institute for a Desensitization Suite
- $147,672 to the Ovations for the Cure of Ovarian Cancer Research Fund at Dana-Farber Cancer Institute through the two AM Fund
- $60,000 to City of Hope Cancer Center in Los Angeles, CA
- $50,000 to University of Pennsylvania's Biomarkers study
- $45,810.50 to Dana-Farber Cancer Institute
- $40,000 to Children's Hospital Boston for Early Detection Research
Get to Know Ursula A. Matulonis, MD
Ursula A. Matulonis, MD, is Director and Disease Center Leader of the Gynecologic Oncology Program at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer.
Dr. Matulonis has led several PARP inhibitor, anti-angiogenic agent and combination trials for ovarian cancer in the United States. Dr. Matulonis serves on the National Comprehensive Cancer Network Recommendation and Guideline committee for ovarian cancer, the Massachusetts Ovarian Cancer Task Force, the NRG ovarian committee, and the Scientific Advisory Board for the Ovarian Cancer Research Foundation Alliance and the Clearity Foundation. She received the Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler “Extra Mile” Award, and the Zakim Award for patient advocacy.
After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute in Boston, MA.
How Your Support Translates into Hope
Ovations for the Cure of Ovarian Cancer has awarded grants to organizations such as Dana-Farber Cancer Institute and Brigham and Women's Hospital. These talented investigators are working to develop tissue and serum biomarkers that will enable early detection, diagnosis and treatment. They are developing new, targeted therapies for the disease while trying to better understand why ovarian cancer cells are initially sensitive to Cisplatin. Also, investigators are focusing on quality of life research and studying how women make critical treatment decisions.